Swiss-Based Ferring Expands Manufacturing to Chinese Port
Ferring Pharmaceutical (China) Co Ltd's opening of its manufacturing site at the Zhongshan port — the Swiss company's first production facility in Asia — is the latest move in Ferring's impressive campaign to extend its operations well beyond its traditional base in Europe.
Ferring's Zhongshan manufacturing plant comprises 20,000 m2. The GMP-compliant plant is designed to be a two-storey factory equipped with multiple production lines, including solutions for injection, lyophilized products, granules and enema, which will strengthen and facilitate Ferring's business development in Asia.
The company has become a leading in the development and sale of pharmaceutical products based on natural pituitary-produced peptide hormone and serves patients in more than 70 countries. In addition to the new Zhongshan plant, it has in-house production sites in Europe, research centres in the US and UK, and a large-scale manufacturing plant being built in Saint-Prex, Switzerland.
Ferring is a Swiss-based research driven, speciality biopharmaceutical group
active in global markets. The company identifies, develops and markets innovative
products in the areas of endocrinology, gastroenterology, gynaecology, infertility
In recent years Ferring has expanded beyond its traditional European base and now has operating subsidiaries in more than 40 countries.